Vaccinogen is a US-based biotechnology company formed in 2007 currently commercializing a personalized immunotherapy designed to prevent disease recurrence after cancer surgery (OncoVAX®). Using a patient’s own tumor as the source material for their treatment, this patented approach has proven to prevent advanced stage II colorectal cancer recurrence with 15 years of patient follow-up compared to surveillance alone. While this Phase IIIb study with Fast Track Designation represents the most near-term source of revenue for the company, new sources of funding will also allow Vaccinogen to develop and commercialize the truly unique, cancer-specific antibodies created by OncoVAX patients into the next product portfolio for the company: bispecific T-cell engagers, antibody-drug conjugates, solid tumor CAR-T, and radioligands with broad specificity against a range of adenocarcinomas – each with pipeline in a product potential. See our website for more details on our science and contact information for investment opportunities.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Baltimore, Md, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vaccinogeninc.com
- Keywords
- Cancer Research and Immunotherapy.
- HQ
- Baltimore, MD
Vaccinogen Questions
Vaccinogen's website is vaccinogeninc.com
Vaccinogen's LinkedIn profile is https://www.linkedin.com/company/vaccinogen-oncovax
Vaccinogen has
9 employees.
View email and phone details for 9
employees at Vaccinogen.
Vaccinogen's industry is
Biotechnology Research
Vaccinogen's top competitors are
Immunoquest Therapeutics,
Neuscience,
Neurogazer Inc.,
Medhemscience Bv,
Ibsrela® (Tenapanor),
Chesapeake Limulabs,
Diagnocure Inc.,
Sensoron,
Profectus Biosciences, Inc,
Hopkins Biotech Podcast.
Vaccinogen's categories are Biotechnology Research
Vaccinogen's founding year is 2007
